

Remarks

Claims 1-73 have been canceled and claims 74-106 have been added.

The new claims have been drafted to address the examiner's comments in the Office Action and the terms objected to by the examiner, including terms that claim subject matter of different scope, are not recited in the new claims. We respectfully submit that this renders the bases for rejection under Section 112 moot.

The newly added claims are directed administration of a therapeutic amount of oxandrolone to treat a wound, wherein the amount of oxandrolone administered is selected to provide a concentration level of 3 micrograms/ml. The specification discloses the importance of procollagen production in wound healing and provides support for the present invention which teaches an effective concentration of oxandrolone to provide such procollagen production and methods for the treatment of wounds by administering oxandrolone in such a therapeutically effective amount. None of the references cited by the Examiner teach or suggest the desirability of selecting an amount of oxandrolone that would provide the claimed oxandrolone concentration. We respectfully submit that this renders the bases for rejection in light of the art moot.

Appl. No. 10/058,066
Amdt. dated April 6, 2005

Conclusion


It is believed that this amendment is fully responsive to the outstanding Office Action, and favorable action is respectfully requested. If a telephone conversation would further the prosecution of the present application, the Examiner is invited to contact the undersigned to resolve any issues that might remain.

Respectfully submitted,

KENYON & KENYON

Date: April 6, 2005

By:



Payam Moradian

Reg. No. 52,048

One Broadway
New York, NY 10004
Telephone: (212) 425-7200
Facsimile: (212) 425-5288